Etavopivat A 100 mg, Etavopivat placebo., Etavopivat A 200 mg
4202-HEM-301
Phase 3 small_molecule active
Quick answer
Etavopivat A 100 mg, Etavopivat placebo., Etavopivat A 200 mg for sickle cell disease (SCD) is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- sickle cell disease (SCD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active